8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
Published . Updated .
Key takeaways
- 8-K - Neumora Therapeutics filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
- Exposed: NMRA
- Market reaction: NMRA +57.4% by the next session (still updating)
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Neumora Therapeutics filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
Directly affected
- NMRA Neumora Therapeutics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Neumora Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+13.5% 30d
Amgen is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+15.3% 30d
Gilead Sciences is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+21.1% 30d
Moderna is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-16.8% 15d
argenx SE is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Neumora Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NMRA | +7.17% | +6.70% | base | +34.60% | +57.44% | after close | after close |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.16% | after close | after close |
| AMGN | -4.55% | -3.07% | base | -0.14% | -0.48% | after close | after close |
| GILD | -7.17% | -6.85% | base | -0.33% | -0.19% | after close | after close |
| MRNA | -10.32% | -3.42% | base | -0.33% | +3.68% | after close | after close |
| ARGX | -2.70% | -0.16% | base | -2.03% | -0.72% | after close | after close |
| RVMD | -3.96% | -1.41% | base | -1.67% | +1.45% | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-10-30 AccNo: 0001193125-26-441634 Size: 139 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Source: sec-edgar
Neumora Therapeutics (NMRA) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | -0.14% | final price |
| AMGN | the next day | -0.48% | still updating |
| AMGN | three days earlier | -3.07% | final price |
| AMGN | five days earlier | -4.55% | final price |
| ARGX | that day | -2.03% | final price |
| ARGX | the next day | -0.72% | still updating |
| ARGX | three days earlier | -0.16% | final price |
| ARGX | five days earlier | -2.70% | final price |
| GILD | that day | -0.33% | final price |
| GILD | the next day | -0.19% | still updating |
| GILD | three days earlier | -6.85% | final price |
| GILD | five days earlier | -7.17% | final price |
| MRNA | that day | -0.33% | final price |
| MRNA | the next day | +3.68% | still updating |
| MRNA | three days earlier | -3.42% | final price |
| MRNA | five days earlier | -10.32% | final price |
| Neumora Therapeutics (NMRA) | that day | +34.60% | final price |
| Neumora Therapeutics (NMRA) | the next day | +57.44% | still updating |
| Neumora Therapeutics (NMRA) | three days earlier | +6.70% | final price |
| Neumora Therapeutics (NMRA) | five days earlier | +7.17% | final price |
| RVMD | that day | -1.67% | final price |
| RVMD | the next day | +1.45% | still updating |
| RVMD | three days earlier | -1.41% | final price |
| RVMD | five days earlier | -3.96% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.16% | still updating |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 38 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 65 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 79 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 81 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 63 days before publication. Filed 8 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Neumora Therapeutics (NMRA)
Companies mentioned with this story
- NMRA Neumora Therapeutics
For “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer),” Neumora Therapeutics (NMRA) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> NMRA
How “8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” reaches Neumora Therapeutics (NMRA)
“8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” (30 Oct 2026) reaches Neumora Therapeutics (NMRA) through this story.
For Neumora Therapeutics (NMRA), the reason on file says SEC 8-K filing -> direct issuer disclosure -> NMRA
Dates and price levels for Neumora Therapeutics (NMRA)
NMRA traded between 0.35 and 0.52 across 4 sessions. The latest close on file is 0.49.
What the saved facts support for Neumora Therapeutics (NMRA)
14 out of 100Price not final
“8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies. The price is not final yet.